Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Successful Sulphide-driven Partial Denitrification: efficiency, stability and resiliency in SRT-controlled conditions

ABSTRACT: The aim of the present work was to maximise NO2- conversion over NO3- reduction coupled with complete sulphide (HS-) oxidation, by the selective control of influent S/N ratio and sludge retention time (SRT). A 2.5-L chemostat was operated for 115 days and three operational phases were tested at decreasing SRT of 40, 23 and 13 h, testing S/N ratios in the range of 0.5-1 gS/gN. Successful sulphide-driven PAD was achieved and lead to average NO2- conversion efficiencies as high as 77±17% at all the conditions tested, with the highest value of 99% at the lowest S/N of 0.58 gS/gN and SRT of 23 h. Respirometric tests showed that NO3- uptake rate was stable at 90±10 mgN/gVSS/h, either when NO3- was present as sole electron acceptor or at NO2- levels as high as 120 mgN/l; on the contrary, NO2- uptake rates were very sensitive to the applied conditions. Metabarcoding analyses revealed that the microbial community was highly enriched in Sulphur Oxidizing Bacteria (SOB>80%) and strict and stable S-limiting conditions appeared to favour Thiobacillus over Sulfurimonas genus. A preliminary assessment of N2O potential emission was also performed. To the best of our knowledge, this is the first work evaluating the synergic effect of SRT and influent S/N ratio on nitrite accumulation in highly SOB-enriched systems and the NO2- conversion efficiencies achieved are among the highest reported in literature.

ORGANISM(S): sulfo-oxidizing enrichment culture

PROVIDER: GSE192713 | GEO | 2022/12/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of mouse germline stem (GS), multipotent germline stem (mGS), and embryonic stem (ES) cells.

Project description:A single spermatogonial stem cell can aquire pluripotentiality but that conversion into a pluripotent cell type is accompanied by loss of spermatogenic potential. We used microarrays to compare the expression profiles among the different stem cell types. Experiment Overall Design: GS, mGS and ES cells were cultured for RNA extraction and hybridization on Affymetrix microarrays. We examined the gene expression profiles of GS and mGS cells to find candidate molecules that are involved in the conversion process of GS into mGS cells.

2008-04-07 | E-GEOD-10610 | biostudies-arrayexpress

Successful Sulphide-driven Partial Denitrification: efficiency, stability and resiliency in SRT-controlled conditions

Project description:Successful Sulphide-driven Partial Denitrification: efficiency, stability and resiliency in SRT-controlled conditions

| PRJNA792821 | ENA

Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis

Project description:Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a life-threatening autoimmune disease that often results in kidney failure caused by crescentic glomerulonephritis (ANCA-GN). To date, treatment of most patients with ANCA-GN relies on unspecific immunosuppressive agents that harbor serious adverse effects and limited efficiency. Using spatial and single-cell transcriptome analysis we characterized inflammatory niches in the kidneys of 34 patients with ANCA-GN and idenjpgied proinflammatory cytokine producing CD4+ and CD8+ T cells as a key pathogenic tissue signature. By employing digital pharmacology we then idenjpgied ustekinumab, a monoclonal antibody targeting IL-12 and IL-23 in these T cells, as promising therapeutic avenue. Based on these findings, four patients with relapsing ANCA-GN were treated with ustekinumab in combination with low-dose cyclophosphamide. Ustekinumab was given subcutaneously (90 mg) at weeks 0, 4, 12, and 24 and clinical and renal response were evaluated at week 26. Treatment induced substantial clinical response in all ANCA-GN patients, with improvements in kidney function, and Birmingham Vasculitis Activity Score, and was well tolerated. Our findings suggest that the pathogenesis-based treatment of ANCA-GN patients with ustekinumab is efficacious and warrants further investigation in clinical trials.

2024-06-28 | GSE250138 | GEO

Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis

Project description:Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a life-threatening autoimmune disease that often results in kidney failure caused by crescentic glomerulonephritis (ANCA-GN). To date, treatment of most patients with ANCA-GN relies on unspecific immunosuppressive agents that harbor serious adverse effects and limited efficiency. By performing spatial and single-cell transcriptome analysis, we characterized inflammatory niches in the kidneys of 34 patients with ANCA-GN and identified pro-inflammatory, cytokine producing CD4+ (TH1 and TH17 subsets) and CD8+ T cells (TC1 and TC17-like subsets) as a key pathogenic signature. Digital pharmacology identified ustekinumab, a monoclonal antibody targeting IL-12 and IL-23 in these T cells, as the most promising therapeutic drug to target. Based on these findings, four patients with relapsing ANCA-GN were treated with ustekinumab in combination with low-dose cyclophosphamide. Ustekinumab was given subcutaneously (90 mg) at weeks 0, 4, 12, and 24 and clinical and renal responses were evaluated at week 26. This treatment was well-tolerated and induced clinical response in all ANCA-GN patients, including an improved kidney function and Birmingham Vasculitis Activity Score. Our findings suggest that the pathogenesis-based treatment of ANCA-GN patients with ustekinumab is efficacious and warrants further investigation in clinical trials.

2024-07-01 | GSE253633 | GEO

Zymomonas mobilis subsp. mobilis ZM4 = ATCC 31821 isolate:ATCC 31821

Project description:Zymomonas mobilis mobilis ZM4 transcriptome - GS-23

| PRJNA409957 | ENA

Project description:no2

| PRJNA1119421 | ENA

Gene expression of cytosolic glutamine synthetase 1;1 knock-out mutant rice

Project description:Rice grown in paddy fields prefers to use ammonium ions as a major source of inorganic nitrogen. Glutamine synthetase (GS) catalyzes the conversion of ammonium ions to glutamine. In three cytosolic GS in rice, OsGS1;1 has the critical role for normal growth and grain filling. To understand a role of GS1;1, we performed transcriptional profiling of wild type Nipponbare and GS1;1 mutant plants in seedling using the Agilent Rice Oligo Microarray.

2010-03-01 | GSE15122 | GEO

Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice

Project description:Lack of non-invasive diagnostic tools and effective therapies constitute two of the major hurdles for a bona fide treatment against non-alcoholic steatohepatitis (NASH) progression and/or regression of nonalcoholic fatty liver disease (NAFLD). Nitro-oleic acid (OA-NO2) has been proven effective in multiple experimental models of inflammation and fibrosis. Thus, the potential benefit of in vivo administration of OA-NO2 to treat advanced NAFLD was studied in a model of long-term NASH diet-induced liver damage. Non-invasive imaging (e.g. photoacustic-ultrasound (PA-US)) was pursued to establish advanced experimental NASH in mice in which both steatosis and fibrosis were diagnosed prior experimental OA-NO2 therapy. CLAMS and NMR-based analysis demonstrates that OA-NO2 improves body composition and energy metabolism and inhibits hepatic triglyceride accumulation. PA-US imaging revealed a robust inhibition of liver steatosis and fibrosis by OA-NO2. RNA-sequencing analysis uncovered inflammation and fibrosis as major pathways suppressed by OA-NO2 administration, as well as regulation of lipogenesis and lipolysis pathways, with a robust inhibition of SREBP1-dependent lipogenic gene expression by OA-NO2. Global liver transcriptome in response to OA-NO2 was confirmed in vivo and in isolated hepatocytes. These results were further supported by histological analysis and quantification of lipid accumulation, lobular inflammation (F4/80 staining) and fibrosis (collagen deposition, αSMA staining) as well as established parameters of liver damage (ALT). In vitro studies indicate that OA-NO2 inhibits TG biosynthesis and accumulation in hepatocytes and inhibits fibrogenesis in human stellate cells. Taken together, OA-NO2 improve steatohepatitis and fibrosis and may constitute an effective therapeutic approach against advanced NAFLD that warrants further clinical evaluation.

2019-02-08 | GSE126204 | GEO

Development of functional anti-Gn nanobodies specific for SFTSV based on next generation sequencing and proteomics

Project description:Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by novel bunyavirus (SFTSV), with a mortality rate of 6.3% ~ 30%. To date, there is no specific treatment for SFTS. Previously, our studies demonstrate that SFTSV surface glycoprotein (Glycoprotein N, Gn) is a potential target for the development of SFTS vaccine or therapeutic antibodies, and anti-Gn neutralizing antibodies play a protective role in SFTS infection. Compared with traditional antibodies, nanobodies from camelids have various advantages including small molecular weight, high affinity, low immunogenicity and convenient production by gene engineering, etc. In this study, we combined next generation sequencing (NGS) with proteomics technology and bioinformatics analysis to high-throughput screen monoclonal anti-Gn nanobodies from camel immunized with Gn protein. We identified 19 anti-Gn monoclonal nanobody sequences, and selected 6 of them for recombinant protein expression and purification. Among these 6 anti-Gn nanobodies, nanobody 57493 was validated to be highly specific for Gn.

2024-01-26 | PXD032731 | Pride

Project description:ESF-SRT

| PRJNA577722 | ENA